Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates.
Inhibition of p70 S6 kinase activity by A77 1726 induces autophagy and enhances the degradation of superoxide dismutase 1 (SOD1) protein aggregates.
复制标题
DOI:
10.1038/s41419-018-0441-0
复制
发表时间:
2018-03-14
影响因子:
9
通讯作者:
Xu X
中科院分区:
文献类型:
--
作者:
Sun J;Mu Y;Jiang Y;Song R;Yi J;Zhou J;Sun J;Jiao X;Prinz RA;Li Y;Xu X
Autophagy plays a central role in degrading misfolded proteins such as mutated superoxide dismutase 1 (SOD1), which forms aggregates in motor neurons and is involved in the pathogenesis of amyotrophic lateral sclerosis (ALS). Autophagy is activated when UNC-51-like kinase 1 (ULK1) is phosphorylated at S555 and activated by AMP-activated protein kinase (AMPK). Autophagy is suppressed when ULK1 is phosphorylated at S757 by the mechanistic target of rapamycin (mTOR). Whether p70 S6 kinase 1 (S6K1), a serine/threonine kinase downstream of mTOR, can also regulate autophagy remains uncertain. Here we report that inhibition of S6K1 by A77 1726, the active metabolite of an anti-inflammatory drug leflunomide, induced mTOR feedback activation and ULK1S757 phosphorylation in NSC34 cells, a hybrid mouse motoneuron cell line. Unexpectedly, A77 1726 did not suppress but rather induced autophagy by increasing AMPKT172 and ULK1S555 phosphorylation. Similar observations were made with PF-4708671, a specific S6K1 inhibitor, or with S6K1 siRNA. Further studies showed that A77 1726 induced AMPK phosphorylation by activating the TGF-β-activated kinase 1 (TAK1). Functional studies revealed that A77 1726 induced co-localization of mutant SOD1G93A protein aggregates with autophagosomes and accelerated SOD1G93A protein degradation, which was blocked by inhibition of autophagy through autophagy-related protein 7 (ATG7) siRNA. Our study suggests that S6K1 inhibition induces autophagy through TAK1-mediated AMPK activation in NSC34 cells, and that blocking S6K1 activity by a small molecule inhibitor such as leflunomide may offer a new strategy for ALS treatment.
登录
查看更多内容
DOI:
10.1126/science.1196371
发表时间:
2011-01-28
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Egan DF;Shackelford DB;Mihaylova MM;Gelino S;Kohnz RA;Mair W;Vasquez DS;Joshi A;Gwinn DM;Taylor R;Asara JM;Fitzpatrick J;Dillin A;Viollet B;Kundu M;Hansen M;Shaw RJ
通讯作者:
Shaw RJ
影响因子:
--
作者:
Chen Y;Huang Q;Zhou H;Wang Y;Hu X;Li T
通讯作者:
Li T
影响因子:
4
作者:
de Oliveira, Gabriela P.;Maximino, Jessica R.;Chadi, Gerson
通讯作者:
Chadi, Gerson
影响因子:
4.8
作者:
Doscas, Michelle E.;Williamson, Ashley J.;Usha, Lydia;Bogachkov, Yedida;Rao, Geetha S.;Xiao, Fei;Wang, Yimin;Ruby, Carl;Kaufman, Howard;Zhou, Jingsong;Williams, James W.;Li, Yi;Xu, Xiulong
通讯作者:
Xu, Xiulong
影响因子:
5.3
作者:
Carunchio, Irene;Curcio, Livia;Zona, Cristina
通讯作者:
Zona, Cristina